2C-I

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2C-I's dose as 14 to 22mg orally and its duration as 6 to 10hours. The effects of 2C-I have been reported to include color enhancement, psychedelic visuals, emotional enhancement, limited insights, increased energy, enhanced conversation and honesty, improved mood, and sensual immersion. The sensual effects of 2C-I were described as different from and possibly less than those of 2C-B. == Interactions ==

2C-I is metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B. Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C-I. This may result in overdose and serious toxicity. ==Pharmacology==

Pharmacodynamics 2C-I acts as a serotonin receptor agonist. It produces psychedelic effects via serotonin 5-HT2A receptor activation. It is inactive as a monoamine releasing agent and shows negligible activity as a monoamine reuptake inhibitor. However, 2C-I showed the highest anti-inflammatory potency of any other assessed drug in a large series in one study. It was more potent than (R)-DOI in terms of anti-inflammatory activity. ==Chemistry==

Synthesis The chemical synthesis of 2C-I has been described. Analogues Analogues of 2C-I include 2C-H (2,5-DMPEA), 2C-B, 2C-C, DOI, 4C-I, and 25I-NBOMe, among others. ==History==

2C-I was first described in the scientific literature by Alexander Shulgin and colleagues in 1977. Its properties and effects in humans were described by Shulgin in 1978. ==Society and culture==

Legal status Australia 2C-I is a schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A schedule 9 drug is outlined in the Poisons Act 1964 as "Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of the CEO". Canada As of October 31, 2016, 2C-I is a controlled substance (Schedule III) in Canada. European Union In December 2003, the European Council issued a binding order compelling all European Union member states to ban 2C-I within three months. Finland It is illegal in Finland, scheduled in the "government decree on substances, preparations and plants considered to be narcotic drugs". Sweden Sveriges riksdag added 2C-I to schedule I ("substances, plant materials and fungi which normally do not have medical use") as a narcotic on March 16, 2004, published by the Medical Products Agency in their regulation LVFS 2004:3. United Kingdom In the United Kingdom,2C-I is controlled as a Class A substance. == See also ==